25-hydroxycholesterol has been researched along with Atrial Fibrillation in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broncel, M; Gorzelak-Pabiś, P; Pawlos, A; Wojdan, K; Woźniak, E | 1 |
1 other study(ies) available for 25-hydroxycholesterol and Atrial Fibrillation
| Article | Year |
|---|---|
Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Cytokines; Dabigatran; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxycholesterols; Interleukin-18; Interleukin-23; Oxysterols; Rivaroxaban; RNA, Messenger; Transforming Growth Factor beta | 2022 |